Carnitine Responsive Migraine Headache Syndrome: Case Report and Review of the Literature.

Carnitine Chronic daily headache Chronic migraine Headache Intractable migraine Mitochondria

Journal

Current pain and headache reports
ISSN: 1534-3081
Titre abrégé: Curr Pain Headache Rep
Pays: United States
ID NLM: 100970666

Informations de publication

Date de publication:
23 Mar 2021
Historique:
accepted: 19 01 2021
entrez: 23 3 2021
pubmed: 24 3 2021
medline: 30 11 2021
Statut: epublish

Résumé

To review carnitine's role in migraine and headache, present a case of a patient with intractable chronic migraine refractory to medications but exquisitely responsive to mitochondrial cofactors with a particularly prompt response to L-carnitine supplementation with dose response, and suggest scenarios where L-carnitine could be considered for prophylactic treatment in migraine and intractable headache with migraine features. Multiple treatments modalities are used to treat migraine, including nutraceutical therapies. Mitochondrial supplements are often used to treat migraine, based on controlled trials. One of the nutraceutical therapies used in neurological and non-neurological conditions is L-carnitine. A few studies have examined the effect of carnitine in patients with migraine. We present a case of a patient with chronic migraine-like headaches found to have carnitine deficiency whose headaches greatly improved with carnitine supplementation. This case suggests that secondary carnitine deficiency may cause chronic migraine. Energy deficiency states occur with migraine, and replenishment of energy substrates has demonstrated some improvement in migraine. Recent studies suggest that L-carnitine with other mitochondrial cofactors may be migraine preventives. The exact link between carnitine and migraine is unknown. Perhaps carnitine deficiency should be in the differential for refractory migraine. Supplementation with L-carnitine merits exploration as a nutraceutical treatment of chronic migraine. Our case suggests that there may be a dose-dependent response to L-carnitine.

Identifiants

pubmed: 33755806
doi: 10.1007/s11916-021-00936-5
pii: 10.1007/s11916-021-00936-5
doi:

Substances chimiques

Carnitine S7UI8SM58A

Types de publication

Case Reports Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

26

Auteurs

Larry Charleston (L)

Department of Neurology, University of Michigan, 1914 Taubman Center, 1500 E. Medical Center Dr. SPC 5316, Ann Arbor, MI, 48109-5316, USA. larrycha@med.umich.edu.

Suad Khalil (S)

Department of Neurology and Ophthalmology, Michigan State University College of Human Medicine, East Lansing, MI, USA.

William B Young (WB)

Department of Neurology, Thomas Jefferson University, Philadelphia, PA, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH